In the last decade, the discovery that IL-1 & IL-6 are key therapeutic targets in systemic juvenile idiopathic arthritis (SJIA) and the introduction of IL-1 and IL-6 inhibiting biologics have led to a dramatic improvement in the outcome of typical features of this disease. Here, IL6 is linked to systemic-onset juvenile idiopathic arthritis.